Free tool
FAERS Monitor: Parnate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012342 or its brand name (Parnate, Tranylcypromine Sulfate). Reports on generic versions are filed under their own applications.
Reports
804
Serious
501
62% of reports
Hospitalization
212
Death reported
40
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective95
- depression91
- drug interaction80
- headache72
- contraindicated product administered68
- nausea63
- insomnia61
- hypertensive crisis60
- anxiety51
- dizziness50
- hypertension50
- suicidal ideation46
- fatigue45
- hyperhidrosis42
- weight increased42
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 45 |
| 2006 | 53 |
| 2007 | 50 |
| 2008 | 59 |
| 2009 | 38 |
| 2010 | 39 |
| 2011 | 51 |
| 2012 | 27 |
| 2013 | 13 |
| 2014 | 12 |
| 2015 | 38 |
| 2016 | 44 |
| 2017 | 25 |
| 2018 | 29 |
| 2019 | 55 |
| 2020 | 30 |
| 2021 | 15 |
| 2022 | 21 |
| 2023 | 30 |
| 2024 | 40 |
| 2025 | 28 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,355 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertensive crisisSignal | 60 | 141.8 | 111.1 | 8,209 |
| contraindicated product administeredSignal | 68 | 58.9 | 46.9 | 3,808 |
| drug interactionSignal | 80 | 13.2 | 10.7 | 896 |
| suicidal ideationSignal | 46 | 13.2 | 9.9 | 506 |
| depressionSignal | 91 | 10.5 | 8.6 | 778 |
| hyperhidrosisSignal | 42 | 8.5 | 6.4 | 273 |
| hypertensionSignal | 50 | 6.2 | 4.7 | 214 |
| insomniaSignal | 61 | 6.0 | 4.7 | 252 |
| weight increasedSignal | 42 | 4.9 | 3.7 | 128 |
| anxietySignal | 51 | 4.7 | 3.6 | 146 |
| headacheSignal | 72 | 3.0 | 2.4 | 97 |
| dizzinessSignal | 50 | 2.6 | 2.0 | 50 |
| nauseaSignal | 63 | 2.1 | 1.6 | 36 |
| drug ineffective | 95 | 1.9 | 1.6 | 41 |
| fatigue | 45 | 1.5 | 1.1 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.